|
Colorectal Neoplasms
|
0.320 |
Biomarker
|
group |
BEFREE |
An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
|
28530155 |
2017 |
|
Colorectal Neoplasms
|
0.320 |
AlteredExpression
|
group |
BEFREE |
Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors.
|
23108143 |
2013 |
|
Colorectal Neoplasms
|
0.320 |
Therapeutic
|
group |
CTD_human |
Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
|
15289873 |
2004 |
|
Neural Tube Defects
|
0.310 |
Biomarker
|
group |
BEFREE |
CSF proteins may be useful in the discovery of potential serum biomarkers for NTDs.
|
28695418 |
2017 |
|
Neural Tube Defects
|
0.310 |
Therapeutic
|
group |
CTD_human |
The incidence of NTDs was 18% in fetuses exposed to VA alone, compared to 3.7% and 2.9% in fetuses exposed to IFN-gamma+VA, or GM-CSF+VA respectively.
|
17075842 |
2006 |
|
Drug toxicity
|
0.300 |
Therapeutic
|
group |
CTD_human |
FIVB plus GM-CSF in metastatic colorectal cancer.
|
7960606 |
1994 |
|
Eyelid Diseases
|
0.300 |
Therapeutic
|
group |
CTD_human |
Valproic acid-induced fetal malformations are reduced by maternal immune stimulation with granulocyte-macrophage colony-stimulating factor or interferon-gamma.
|
17075842 |
2006 |
|
Adverse reaction to drug
|
0.300 |
Therapeutic
|
group |
CTD_human |
FIVB plus GM-CSF in metastatic colorectal cancer.
|
7960606 |
1994 |
|
Inflammatory disease of mucous membrane
|
0.300 |
Biomarker
|
group |
CTD_human |
Although the granulocyte nadirs were significantly lower at each 5-FU dose level with the concurrent GM-CSF schedule (eg, 490 mg/m2/d: median, 879/microL v3,286/microL; two-tailed P [P2] < .001), dose-limiting granulocytopenia complicated < or = 16% of cycles with 5-FU < or = 560 mg/m2/d (99 cycles); > or = grade 3 mucositis occurred in < or = 20% of cycles.
|
8120554 |
1994 |
|
Parkinsonian Disorders
|
0.240 |
Biomarker
|
group |
BEFREE |
We analyzed the CSF biomarker profile (Aβ<sub>42</sub>, τ<sub>T</sub>, τ<sub>P-181</sub>, α-syn) and all relevant ratios in 68 patients with Parkinsonism (19 PSP, 15 MSA, 17 CBD, 17 PD) and 18 controls, diagnosed by latest established diagnostic criteria.
|
29111028 |
2017 |
|
Parkinsonian Disorders
|
0.240 |
Biomarker
|
group |
BEFREE |
To investigate the CSF biomarkers' (NF-L, t-tau, and p-tau) relationship to mortality in parkinsonian disorders.
|
31070772 |
2019 |
|
Parkinsonian Disorders
|
0.240 |
Biomarker
|
group |
RGD |
Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease.
|
21291297 |
2011 |
|
Parkinsonian Disorders
|
0.240 |
Biomarker
|
group |
BEFREE |
CSF Aβ1-42 level was decreased in CNGA patients with parkinsonism (β: - 189.4; 95% CI [- 352.3; - 26.6]; p = 0.024) even after adjusting for age, gender, comorbidities, and total white matter burden; while CSF total tau and phosphorylated tau levels were similar between CNGA patients with and without parkinsonism.
|
29843235 |
2018 |
|
Parkinsonian Disorders
|
0.240 |
Biomarker
|
group |
BEFREE |
To determine if blood neurofilament light chain (NfL) protein can discriminate between Parkinson disease (PD) and atypical parkinsonian disorders (APD) with equally high diagnostic accuracy as CSF NfL, and can therefore improve the diagnostic workup of parkinsonian disorders.
|
28179466 |
2017 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) produced by T helper 17 (Th17) cells plays an essential role in autoimmune diseases.
|
29222492 |
2017 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Granulocyte-macrophage colony-stimulating factor as a mediator of autoimmunity in multiple sclerosis.
|
30196820 |
2018 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The development of the adult form of human alveolar proteinosis is not due to the absence of a GM-CSF gene or receptor defect but to the development of an anti-GM-CSF autoimmunity.
|
12896880 |
2003 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Organ-specific autoimmunity in granulocyte macrophage-colony stimulating factor (GM-CSF) deficient mice.
|
11908710 |
2002 |
|
Autoimmune Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Specifically, the cellular processes related to cell proliferation (for example, epidermal growth factor, platelet-derived growth factor, nuclear factor-κB, Wnt/β-catenin signaling, stress-activated protein kinase c-Jun NH2-terminal kinase), inflammatory response (for example, interleukins IL2 and IL6, the cytokine granulocyte-macrophage colony-stimulating factor and the B-cell receptor), general signaling cascades (for example, mitogen-activated protein kinase, extracellular signal-regulated kinase, p38 and TRK) and apoptosis are activated in most of the analyzed autoimmune diseases.
|
23190644 |
2013 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
GM-CSF-mediated inflammation has also been implicated in certain types of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.
|
25803788 |
2015 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic, Th17-derived cytokine thought to critically contribute to the pathogenesis of diverse autoimmune diseases, including rheumatoid arthritis and psoriasis.
|
28777803 |
2017 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This review summarizes the evidence supporting a major role for GM-CSF in inflammation and autoimmunity and its functions as major regulator governing granulocyte and macrophage lineage populations at all stages of maturation.
|
16167889 |
2005 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We have shown that activin A, a cytokine implicated in regulating B-cell proliferation, is severely deficient in alveolar macrophages from patients with pulmonary alveolar proteinosis (PAP), an autoimmune disorder characterized by surfactant accumulation and neutralizing autoantibodies to granulocyte-macrophage colony stimulating factor.
|
18803071 |
2009 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This study suggests that Cbl-b limits autoimmunity by preventing the pathogenic effects of GM-CSF overproduction in T cells.
|
30349541 |
2018 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Granulocyte-macrophage colony-stimulating factor (GM-CSF or Csf-2) is a pro-inflammatory mediator implicated in the pathogenesis of various autoimmune diseases.In this issue of Immunity, Spath et al.
|
28228272 |
2017 |